CTOs on the Move

BioCentriq

www.biocentriq.com

 
BioCentriq was founded in 2018 and is a full service CDMO for cell and gene therapy process development and clinical manufacturing. Our ISO-7 certified GMP clinical manufacturing facility is in Newark, NJ. At this facility, we manufacture autologous and allogeneic cell therapies, gene therapies and provide analytical and quality services across several cell types. We offer viral vector production, cell and viral banking and upstream and downstream processing. Additionally, we have the capabilities to manufacture immunotherapies, including monoclonal antibodies and proteins, and vaccines. Our facilities provide full customer access to work in hybrid teams from tech transfer through GMP clinical ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Powerpollen

PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices.

Tizona Therapeutics

Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.

Helsinn Therapeutics (US)

Helsinn Therapeutics (US) is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aptinyx

Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical need.